GGrantIndex
← Leaderboards

Robert J Parmer

University Of California San Diego

$2,470,759
Attributed
$4,459,337
Total exposure
9
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $786.1K · FY200522
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$4,459,337 · 7
VA$0 · 2

By mechanism

R01$3,406,383 · 2
P01$666,198 · 1
U01$318,627 · 1
M01$68,129 · 3
I01$0 · 2

Top collaborators

Most similar at University Of California San Diego

Same institution · by research overlap

Others in their field

Top investigators on “Plasminogen

Research focus

PlasminogenHypertensionPathway InteractionsAffectIn VivoAdultResponseMediatingIn VitroProteinsPlasminogen ReceptorPlayRegulationPlasminPhenotypeHuman SubjectFamily GeneticsBaseFibrosisFibrinCause Of DeathFibrinogenHomeostasisEquilibrium

Grant awards (26)

A Novel Plasminogen Receptor Promotes Adipose Function and Metabolic Homeostasis$732,257
R01 · FY2022 · HL
A Novel Plasminogen Receptor Promotes Adipose Function and Metabolic Homeostasis$732,257
R01 · FY2021 · HL
Regulation of Renal Injury and Fibrosis by the Plasminogen Receptor, Plg-RKT$0
I01 · FY2021 · VA · contact PI
A Novel Plasminogen Receptor Promotes Adipose Function and Metabolic Homeostasis$732,257
R01 · FY2020 · HL
Regulation of Renal Injury and Fibrosis by the Plasminogen Receptor, Plg-RKT$0
I01 · FY2020 · VA · contact PI
A Novel Plasminogen Receptor Promotes Adipose Function and Metabolic Homeostasis$786,096
R01 · FY2019 · HL
Regulation of Renal Injury and Fibrosis by the Plasminogen Receptor, Plg-RKT$0
I01 · FY2019 · VA · contact PI
Regulation of Renal Injury and Fibrosis by the Plasminogen Receptor, Plg-RKT$0
I01 · FY2018 · VA · contact PI
Cell Surface Plasminogen Activation and Hypertension$0
I01 · FY2016 · VA · contact PI
Cell Surface Plasminogen Activation and Hypertension$0
I01 · FY2015 · VA · contact PI
Cell Surface Plasminogen Activation and Hypertension$0
I01 · FY2014 · VA · contact PI
Cell Surface Plasminogen Activation and Hypertension$0
I01 · FY2013 · VA · contact PI
RENAL DOPAMINERGIC PHARMACOGENOMICS$525
M01 · FY2006 · RR · contact PI
RENAL DOPAMINERGIC PHARMACOGENOMICS$37,854
M01 · FY2005 · RR
GENETIC HYPERTENSION$7,326
M01 · FY2005 · RR
Genetic Hypertension$22,424
M01 · FY2004 · RR
Phenotyping--pharmacodynamic renal dopaminergic responses in pedigrees$318,627
U01 · FY2002 · HL
HEREDITARY AUTONOMIC INTERMEDIATE PHENOTYPES IN HYPERTENSION$159,403
P01 · FY2002 · HL
HEREDITARY AUTONOMIC INTERMEDIATE PHENOTYPES IN HYPERTENSION$159,403
P01 · FY2002 · HL
Phenotyping--pharmacodynamic renal dopaminergic responses in pedigrees$0
U01 · FY2002 · HL
PROCESSING OF CHROMOGRANIN A BY THE FIBRINOLYTIC SYSTEM$214,888
R01 · FY2001 · HL
HEREDITARY AUTONOMIC INTERMEDIATE PHENOTYPES IN HYPERTENSION$159,403
P01 · FY2001 · HL
Phenotyping--pharmacodynamic renal dopaminergic responses in pedigrees$0
U01 · FY2001 · HL
Phenotyping--pharmacodynamic renal dopaminergic responses in pedigrees$0
U01 · FY2001 · HL
PROCESSING OF CHROMOGRANIN A BY THE FIBRINOLYTIC SYSTEM$208,628
R01 · FY2000 · HL
HEREDITARY AUTONOMIC INTERMEDIATE PHENOTYPES IN HYPERTENSION$187,989
P01 · FY2000 · HL